Evidence of a tumour suppressive function of E2F1 gene in human breast cancer
- PMID: 18751386
Evidence of a tumour suppressive function of E2F1 gene in human breast cancer
Abstract
Background: The E2F family of transcription factors are key regulators of genes involved in cell cycle progression, cell fate determination, DNA damage repair and apoptosis. E2F1 is unique in that it contributes both to the control of cellular proliferation and cellular death. Furthermore, unlike other E2Fs, E2F1 responds to various cellular stresses. This study aimed to examine the level of mRNA expression of E2F1 gene in normal and malignant breast tissue and correlate the level of expression to tumour stage.
Materials and methods: One hundred and twenty-seven breast cancer tissue and 33 normal tissues were analyzed. Levels of transcription of E2F1 were determined using real-time quantitative PCR, normalized against CK19. Levels of expression were analyzed against TNM stage, nodal involvement, tumour grade and distant metastasis.
Results: The levels of E2F1 mRNA were lower in malignant tissues. They declined further with increasing TNM stage. This became statistically significant when TNM stages 3 and 4 were compared to TNM stages 1 and 2 disease (TNM1 vs. TNM3 p = 0.032; TNM1 vs. TNM4 p = 0.032; TNM2 vs. TNM3 p = .019; TNM2 vs. TNM4 p = 0.021). The levels of E2F1 also fell with increasing tumour grade, when comparing grade 2 and 3 with grade 1, however, the differences were not statistically significant.
Conclusion: These results are highly suggestive of the role of E2F1 as a tumour suppressive gene in human breast cancer.
Similar articles
-
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.Anticancer Res. 2006 Nov-Dec;26(6C):4985-90. Anticancer Res. 2006. PMID: 17214375
-
Evidence for a tumour suppressive function of APRG1 in breast cancer.Breast Cancer Res Treat. 2005 Sep;93(2):97-100. doi: 10.1007/s10549-005-4169-z. Breast Cancer Res Treat. 2005. PMID: 16187228
-
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.Breast Cancer Res Treat. 2006 Sep;99(2):155-62. doi: 10.1007/s10549-006-9198-8. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541304
-
Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer.Anticancer Res. 2007 Sep-Oct;27(5B):3513-8. Anticancer Res. 2007. PMID: 17972510
-
E2F1 in gliomas: a paradigm of oncogene addiction.Cancer Lett. 2008 May 18;263(2):157-63. doi: 10.1016/j.canlet.2008.02.001. Epub 2008 Mar 10. Cancer Lett. 2008. PMID: 18334281 Review.
Cited by
-
MicroRNA-1298-5p inhibits the tumorigenesis of breast cancer by targeting E2F1.Oncol Lett. 2021 Sep;22(3):660. doi: 10.3892/ol.2021.12921. Epub 2021 Jul 13. Oncol Lett. 2021. PMID: 34386082 Free PMC article.
-
Correlation of expression of Akt1 and E2F1 and their phosphorylated forms in breast cancer patients with clinicopathological parameters.J Mol Histol. 2021 Jun;52(3):621-633. doi: 10.1007/s10735-021-09973-1. Epub 2021 Apr 13. J Mol Histol. 2021. PMID: 33847878
-
Low E2F2 activity is associated with high genomic instability and PARPi resistance.Sci Rep. 2020 Oct 21;10(1):17948. doi: 10.1038/s41598-020-74877-1. Sci Rep. 2020. PMID: 33087787 Free PMC article.
-
Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis.PeerJ. 2020 Sep 29;8:e9946. doi: 10.7717/peerj.9946. eCollection 2020. PeerJ. 2020. PMID: 33083112 Free PMC article.
-
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.Cells. 2020 Jul 8;9(7):1643. doi: 10.3390/cells9071643. Cells. 2020. PMID: 32650578 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous